## ALM LAW.COM

## AM LAW LITIGATION DAILY

## Litigator of the Week Runners-Up and Shout-Outs

**By Ross Todd**November 8, 2024

- Nick Schlossman secured a win for Avadel CNS Pharmaceuticals allowing it to continue marketing and selling its narcolepsy drug Lumryz, which has a once-nightly dosing regimen. Jazz Pharmaceuticals, the maker of twice-nightly narcolepsy drugs, sued the Food and Drug Administration in 2023, challenging the approval of Lumryz, and Avadel, represented by Latham, intervened. U.S. District Judge Amit Mehta in Washington, D.C. last week granted summary judgment to Avadel, finding that the FDA had reasonably concluded "once-nightly dosing offers a better chance at achieving less disrupted sleep" and that the agency's approval of Lumryz was not arbitrary or capricious. Perry argued the summary judgment motion for Avadel. The team also included partner John Manthei and counsel Amy Speros and associates Richard Frohlichstein, William Seidleck, Kimon Triantafyllou, Alex Siemers, Joseph Sitzmann, Alon Handler and Lia Barrett.
- ➤ Shout-out to teams at Latham and Wilson Sonsini that represent The Trade Desk and its board of directors in a case concerning the company's decision to redomicile from Delaware to Nevada. Delaware Vice Chancellor Paul A. Fioravanti Jr. granted summary judgment this week to the company and the board in a lawsuit brought by a shareholder who was seeking to force the company to obtain a two-thirds stockholder majority, rather than a simple majority, to go through with the conversion. The Latham team included Colleen Smith, who argued on behalf of the defendants last week, partners Blair Connelly and Zach Rowen, counsel Thomas Giblin and Ryan Walsh and associates Alexander Mills, Scott Levinson and Allie O'Hara. The Wilson Sonsini team included Brad Sorrels, David Berger, Andrew Cordo, Nora Crawford, Lauren DeBona and Jacqueline Conner.